

Virchow Group

Your trusted Pharmaceutical Solutions Partner

Virchow group comprises of a dedicated marketing cell, eight active pharmaceutical ingredient (API) and drug intermediate manufacturing units and two biotech units. Incorporated in 1981, the umbrella company of the group, Virchow Laboratories Ltd., is today the largest producer of Sulfamethoxazole in the world. In fact, Virchow Group services more than 80% of the worldwide Sulfamethoxazole requirement. Other group companies are leading manufacturers of Ranitidine, Cephalosporins and various other APIs and biopharmaceuticals. Virchow also undertakes custom synthesis and manufacture of drug intermediates.

Over the past decade, Virchow Healthcare Pvt. Ltd. has been working closely with various channel partners across more than 20 countries to market advanced finished formulations in their markets.

The Production facilities are state of the art with efficient modern equipment and optimized production processes for large-scale production. Most of the products are manufactured in dedicated production facilities with dedicated equipment as per current Good Manufacturing Practices (cGMPs). All the units have been audited and approved for cGMP compliance by various national and international regulatory agencies.

Today, the Virchow Group of Companies are reliable suppliers to various pharmaceutical giants and markets worldwide.

RC

Covalent Laboratories (P) Limited

Forging ahead in Cephalosporins

Covalent Laboratories Private Limited is a multi-product oral and sterile Cephalosporin API manufacturing facility, with a capacity of 1200 MT of Cephalosporin API's per annum. Covalent concentrates on the production of newer 2nd, 3rd and 4th generation Cephalosporin API's and their intermediates. The facilities are equipped to handle a wide variety of reactions at varying temperatures. Covalent manufactures most of the critical intermediates in-house and is currently one of the largest producers of Cefixime in the world. Covalent's production facility has been audited and approved by various regulatory agencies including the Korean FDA and US FDA.

Certifications

- ISO 9001-2000
- ISO 14001
- WHO-GMP
- Korea FDA
- US FDA



Virchow Drugs Limited

Concentrating on small API's

Virchow Drugs Limited has two production facilities: Unit-I located in Hyderabad and Unit-II in Pharma City, Vishakhapatnam. Unit-I focuses on the production of small volume Sulfa molecules leveraging on in-house production of Acetyl Sulfanilyl Chloride (ASC), the common moiety for all Sulfa molecules. Unit-II is a multi-product small volume API production plant with reactor capacities ranging from 1 to 5 KL and a variety of powder processing equipment enabling production of varied APIs with different physical properties. Virchow Drugs holds WHO-GMP certification.



Products

- Itraconazole
- Telmisartan
- Olmesartan
- Sulfapyridine

RC


Virchow Healthcare (P) Limited

Healthcare solutions for the world

Incorporated in the year 2008 with a vision to deliver advanced biological and pharmaceutical formulations to various markets, Virchow Healthcare (P) Limited (VHPL) has taken strides to create a trusted presence in over 20 countries across the globe. VHPL continuously strives to meet the stringent regulatory standards whilst offering an array of complex unique products with outstanding quality at competitive prices.

Focusing on Advanced Wound Care, Orthopedics, Anti-thrombotics, Oncology, Blood & Plasma products, Anti-retrovirals, Cardio-Diabetics, Probiotics, Ophthalmics, Cephalosporins, and Nutraceuticals amongst other segments, VHPL holds a strong and vast portfolio.

Its highly qualified and experienced team with a meticulous focus on customer service has enhanced the marketing efforts of its partner firms.



Regulatory Approvals

- WHO-GMP
- PIC/S (Ukraine)
- PPB (Kenya)
- NAFDAC (Nigeria)
- NDA (Uganda)
- FDA (Ghana)

Current Markets

- South-East Asia
- Africa
- Russia-CIS
- Latin & South America

Virchow Biotech (P) Limited

Bio-pharmaceuticals for life

Incorporated in 2001, Virchow Biotech (P) Limited (VBPL), the bio-pharmaceutical company of the group focuses on the manufacturing of a wide range of biologicals and bio-generics by genetic engineering, classical fermentation or extraction technologies. VBPL's achievements include being the first company in the world to commercialize bio-generics of PDGF, Teriparatide, Pegylated Interferon and Rasburicase. Currently the product portfolio consists of fifteen products with five other recombinant bio generics in pipeline. Apart from these, other non-biologicals are also manufactured. VBPL's cGMP facilities, accredited by various regulatory agencies from around the world, consist of 7 independent production suites with a total built-up area of 125,000 ft².

Certifications

- ANVISA (Brazil)
- CE
- INVIMA (Colombia)
- ISO 13485:2012
- PIC/S (Ukraine)
- WHO-GMP
- US FDA



Virchow Laboratories Limited

The world leader in Sulfamethoxazole

Virchow Laboratories Limited (VLL) is the largest producer of Sulfamethoxazole in the world with an output of 4,000 MT per annum. The Virchow plant is located on a spread of 18 acres in Hyderabad, India. Virchow produces all the critical high purity raw materials and intermediates such as Oxalic acid, Sodium Methoxide, Isoxamine and N-Acetyl sulfanilyl chloride in-house in production facilities dedicated to the production of Sulfamethoxazole.

VLL has been audited by various regulatory agencies including the US FDA and is the preferred supplier of Sulphamethoxazole to Glaxo Smithkline, Hoffman La Roche, Shionogi & Co., and various US generic manufacturers.

Certifications

- Certificate of Suitability (CEP 1999-172)
- COFEPRIS, Mexico
- ISO 9001-2000
- ISO 14001
- PMDA, JAPAN
- WHO-GMP
- USFDA



Andhra Organics Limited

Focusing on large volume APIs

Andhra Organics Limited (AOL), established in 2002, is located on a spread of 100 acres. AOL is today the largest production facility within the Virchow Group, with 15 production blocks and over 1500 KL reactor capacity. AOL's production facilities are vertically integrated with efficient solvent recovery systems enabling cost efficient production of large volume intermediates and APIs. AOL holds WHO-GMP certification for its products, and its production facilities have been audited and approved by various regulatory agencies including the US FDA.




Products

- Sulfamethoxazole
- Trimethoprim
- Sulfanilamide
- Cis-Lactam (Intermediate of Diltiazem)

Saraca Laboratories Limited

Growing beyond Ranitidine

Saraca Laboratories was established in 1992 with an aim to manufacture Bulk Drugs and Intermediates. Saraca started production of Ranitidine HCL in 1998 and in a short span of time has become the world's largest manufacturer of Ranitidine and its intermediates (NMSM and Cistophur base). Saraca has two production plants: Unit-1 located in Hyderabad in an area of 30 acres with 4 production blocks and over 100 reactors; and Unit-2 located in Vishakhapatnam in an area of 30 acres with 2 production blocks and 60 reactors. A full-fledged R&D center and pilot plant complement the production facilities. Saraca has been audited and approved by various regulatory agencies including the Korean FDA and US FDA.



Certifications

- Certificate of Suitability (CEP 2004-057)
- Korea FDA
- WHO-GMP
- US FDA

Emmennar Pharma Private Limited

Innovating, in more ways than one

Emmennar Pharma Private Limited, established in 2003, is one of the world's largest manufacturers of Tramadol HCl & Ciprofloxacin HCl. Emmennar has three manufacturing facilities out of which one is API and two are intermediate facilities with a combined capacity of 1000 KL. There are separate manufacturing blocks for Prostaglandins and high potent APIs. Emmennar has a dedicated R&D Center recognized by the Government of India which is led by more than 100 scientists.

Certifications

- WHO-GMP
- CEP for Tramadol HCL
- ISO 9001:2000
- ISO 14001



